Tradestie Institutional Equity Comparison Engine
THOR vs IART โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IART Overall Edge
IART Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Integra LifeSciences Holdings (IART) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, THOR trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus IART at 5.6x Forward P/E and 9.9% operating margin (+2.3% YoY). In options structure, THOR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IART sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
IART
THOR N/M vs IART 5.6x Fwd P/E
Growth & Margin Winner
IART
Op Margin N/A vs 9.9% ยท YoY N/A vs +2.3%
Momentum & Technical Winner
IART
1Y -1.4% vs +18.8% ยท 52W Pos 2% vs 39%
Options & Structure Winner
IART
UNCLASSIFIED (N/A IV) vs BREAKDOWN (16th %ile IV)
THOR
US Equity
THOR
Institutional Equity
$24.63
-1.7% 1D
Market Cap
N/A
1M Return
-3.92%
1Y Return
-1.43%
Forward P/E
N/M
Unified AI Score
44.5 / 100
HOLD
Tech 27.0
Fund 50.0
Flow 50.0
Mom 60.0
IART
NASDAQ
Integra LifeSciences Holdings
Surgical & Medical Instruments & Apparatus
$13.25
-2.21% 1D
Market Cap
$1.1B
1M Return
+7.51%
1Y Return
+18.83%
Forward P/E
5.6x
Unified AI Score
45.5 / 100
HOLD
Tech 43.0
Fund 53.0
Flow 68.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
THOR -1.43%
IART +18.83%
Spread: +23.67 pp (THOR Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
THOR TTM Op. Margin: N/A
IART TTM Op. Margin: 9.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on THOR vs IART. Trailing 12-month operating profitability (THOR N/A vs IART 9.9%) and valuation multiples (THOR N/M vs IART 5.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | THOR | IART | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $1.1B | Larger Scale | IART |
| Trailing P/E Ratio Valuation | N/M | 79.7x | Lower Multiple | IART |
| Forward P/E Ratio Valuation | N/M | 5.6x | Lower Multiple | IART |
| Revenue Growth (YoY) Growth | N/A | +2.3% | Higher Growth | IART |
| Operating Margin (TTM) Profitability | N/A | 9.9% | Higher Margin | IART |
| Net Profit Margin Profitability | N/A | 0.8% | Higher Margin | IART |
| Return on Equity (ROE) Capital Efficiency | N/A | 1.2% | Higher ROE | IART |
| 52-Week Range Position Momentum | 2% ($25โ$29) | 39% ($9โ$20) | Stronger Trend | IART |
| Beta / 30D Volatility Risk Regime | 0.46ฮฒ ยท 17% Vol | 1.54ฮฒ ยท 60% Vol | Lower Realized Risk | THOR |
| Unified Institutional Score Composite Signal | 44.5 / 100 (HOLD) | 45.5 / 100 (HOLD) | Higher Composite | IART |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full THOR vs IART Buy Guide
THOR
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
IART
BREAKDOWN
103d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
16th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither THOR nor IART registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.